Phase II study of VELCADDE in patients with extranodal marginal zone B-cell lymphoma of MALT type pretreated with more than one prior systemiuc therapy regime
- Conditions
- treatment of relapsed extranodal marginal zone B cell non Hodgkin lymphoma of MALT type with bortezomibMedDRA version: 9.1Level: LLTClassification code 10015823Term: Extranodal marginal zone B-cell lymphoma (MALT type) recurrent
- Registration Number
- EUCTR2004-004596-11-IT
- Lead Sponsor
- INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method